Ionis Pharmaceuticals, Inc.

IONSintermediary

Ionis Pharmaceuticals is the leader in antisense technology, an approach that uses short strands of modified DNA to silence disease-causing genes at the RNA level. With Spinraza transforming SMA treatment and a rich pipeline of next-generation LICA platform drugs, Ionis is transitioning from a royalty-dependent model to a fully integrated rare disease company.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($1.8B)

静态数据（加载实时财务…）

Royalties (Spinraza) (30%)

Product Revenue (Wainua) (25%)

Collaboration & Licensing (35%)

R&D Services (10%)

业务板块构成与主要客户

产品详情

Spinraza (Nusinersen)35%

Antisense therapy for spinal muscular atrophy, partnered with Biogen

Wainua (Eplontersen)35%

Next-gen LICA antisense for hereditary ATTR polyneuropathy

Pipeline Medicines30%

Olezarsen (cardiovascular), donidalorsen (HAE), and CNS programs

供应链关系

竞争对手

Alnylam Pharmaceuticals, Inc.

ATTR treatments (antisense vs RNAi)

影响: Direct therapeutic competitor

合作伙伴

Pfizer Inc.

Obesity antisense collaboration

影响: Major pharma partnership

Eli Lilly and Company

Neurological disease pipeline collaboration

影响: Strategic R&D partner

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Ionis Pharmaceuticals, Inc. 的 AI 供应链分析。

企业信息

总部

Carlsbad, California, USA

成立时间

1989

员工人数

2,600+

官网

ionispharma.com

行业概况 — 제약 / 바이오

行业新闻